To include your compound in the COVID-19 Resource Center, submit it here.

Vascepa icosapent ethyl regulatory update

Amarin said FDA's Office of New Drugs denied Amarin's appeal of FDA's rescission of the SPA for the Phase III ANCHOR trial evaluating Vascepa icosapent

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE